Haystack Oncology, a Quest Diagnostics company, and Rutgers Cancer Institute are partnering to evaluate the use of Haystack MRD, a circulating tumor DNA minimal residual disease test, to help optimize postoperative therapy decisions in patients with stage 2/3 non-small cell lung cancer.
Christian Hinrichs, co-director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence and chief of the Section of Cancer Immunotherapy, RWJBarnabas Health, has been awarded a four-year, $800,000 translational research grant from the V Foundation for Cancer Research to develop next-generation immunotherapies for cancers caused by human papillomavirus.
